Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. - Wikidata - wikimedia - TriplyDB

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.

http://www.wikidata.org/entity/Q37273485

about

FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside Proteasome inhibitors in mantle cell lymphoma Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.Inhibitory kappa B Kinases as targets for pharmacological regulation.Cancer Tissue Engineering: A Novel 3D Polystyrene Scaffold for In Vitro Isolation and Amplification of Lymphoma Cancer Cells from Heterogeneous Cell Mixtures.Bortezomib in the treatment of mantle cell lymphoma.The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.Targeting IκappaB kinases for cancer therapy.

P2860

Q30535265-5A3E41B8-C0A2-47D5-B394-EDC6137C4136 Q34997715-2F9276B4-48F2-4AE8-BA8C-718924D182BA Q35050501-798FDACA-DFDA-4DCD-8CBE-CB26142E64AC Q35779961-03A5942C-4596-4A13-8F1B-B084B7EF5776 Q35905929-9D2F5154-D569-4324-AC7C-6AC41EA4850E Q35989980-924DD019-A31C-4B0E-8FE8-A25620B8FDF7 Q36028745-E3BDFCC6-5B62-4244-872A-50D3324C8374 Q36278006-99ECBE16-BA77-4D27-BFA3-E9619AD52873 Q37646739-D10F0799-BAAD-431B-9BC7-417A32EDB961 Q37907354-C09026A6-525D-4039-A60D-F53E7DA01053 Q38342904-3DA57C7C-06B2-411C-9C8C-10DD729F1197 Q38582650-A6D3A17E-D3F6-4A0E-BBD9-CE4EABA903F7 Q39029195-3FB42127-C22E-45E5-985C-A42536572A9F Q52372117-844223CD-FEFD-4120-89C3-E988CF25E397

P2860

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.

http://www.wikidata.org/entity/Q37273485

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Combination bortezomib and rit ...... tosis in mantle cell lymphoma.

@en

Combination bortezomib and rit ...... tosis in mantle cell lymphoma.

@nl

type

label

Combination bortezomib and rit ...... tosis in mantle cell lymphoma.

@en

Combination bortezomib and rit ...... tosis in mantle cell lymphoma.

@nl

prefLabel

Combination bortezomib and rit ...... tosis in mantle cell lymphoma.

@en

Combination bortezomib and rit ...... tosis in mantle cell lymphoma.

@nl

P1433

Q37273485-825D601D-63EA-4183-AC57-2C0DA013116A

P1476

Q37273485-FCBE0A89-5F32-4C21-AE3C-4E8B423F9C0F

P2093

Q37273485-05B14E85-434B-4737-92EA-0E5C49AE39A9

Q37273485-11FC119E-D520-4C81-9D55-4CE918DC7B08

Q37273485-15315FA3-F34A-4BDE-8DAF-F9AC0EA95A64

Q37273485-199B3536-16C2-4378-BB91-47A514DC3673

Q37273485-295AF987-983D-4E8D-9728-B1CD78369C7C

Q37273485-31243B50-EBC8-4B51-883C-DA94AC11654D

Q37273485-54864CA5-2C24-4D13-B9E6-A14DB9E44769

Q37273485-57B97014-1378-4688-A957-A52125AE3DD2

Q37273485-A5A06C44-F1E0-4C62-A7A5-E62E01D52C75

Q37273485-B7AB7D69-6CD2-4A4F-A593-75DB2B30EED1

P2860

Q37273485-04167AE0-2616-4CBA-B7B6-0CD4C527BAED

Q37273485-06809AC9-C64E-411E-A0F8-740F38941753

Q37273485-0C041841-69CF-4CCB-906E-4A00A08102E6

Q37273485-16631922-FC36-4423-BBA0-92982AFA6CE1

Q37273485-1E9458D2-536A-4FBC-86FC-A6A919027746

Q37273485-2CC7BD62-4AFC-4F0D-A707-4F474C58D1AF

Q37273485-2F7DD382-0709-49A9-9651-F288CE1F8977

Q37273485-3B00FB9F-F6A2-4834-973F-77AAB7E19317

Q37273485-3CBE387C-CD38-4F37-BA3C-13F0E5B8CBE1

Q37273485-3DF58C99-D928-43C7-947C-20F8F5C11B86

P304

Q37273485-CC63789A-0B22-49EF-A93B-D9E5827EC770

P31

Q37273485-4E511F5B-539F-4F0F-8275-B1A9E1D8B266

P356

Q37273485-87CAE729-9D84-4F5A-A5CA-4A99EE58B343

P433

Q37273485-DD135093-808D-4FA9-9051-E6F447CF8BD8

P478

Q37273485-204313C6-BD7E-470D-A59D-53DE86D9B413

P50

Q37273485-C7379E63-E8DD-400D-94D1-883BD10BAB0F

P577

Q37273485-CBFE0DBC-6EB3-4FAE-91AE-935A2113A1F6

P5875

Q37273485-98362F72-8AC4-4CCC-A126-83B2B3325006

P698

Q37273485-D6C2405F-661C-481F-82E7-2E68EAAFEF9C

P921

Q37273485-E40A796E-3744-4E6D-9175-2E0C44494018

P932

Q37273485-250E89A8-F51A-4624-8472-9ACB0F0F9ACC

P356

P1433

Monoclonal Antibodies

P1476

Combination bortezomib and rit ...... tosis in mantle cell lymphoma.

@en

P2093

Amy K Ferketich

http://www.w3.org/2001/XMLSchema#string

Christian T Earl

http://www.w3.org/2001/XMLSchema#string

David M Lucas

http://www.w3.org/2001/XMLSchema#string

James T Dalton

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Johnston

http://www.w3.org/2001/XMLSchema#string

Kristie A Blum

http://www.w3.org/2001/XMLSchema#string

Lapo Alinari

http://www.w3.org/2001/XMLSchema#string

Pierluigi Porcu

http://www.w3.org/2001/XMLSchema#string

Raymond Lai

http://www.w3.org/2001/XMLSchema#string

Robert A Baiocchi

http://www.w3.org/2001/XMLSchema#string

P2860

NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis

Characterization of 4 mantle cell lymphoma cell lines

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

Mantle-cell lymphoma.

c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells

P304

31-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.1.1.7472

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40834628

http://www.w3.org/2001/XMLSchema#string

P698

20046572

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

2715189

http://www.w3.org/2001/XMLSchema#string